ENCLAI Evidence Digest

Once a month: four features, one per therapeutic area, chosen by patient impact from the studies and drug approvals ENCLAI reported. Every number is checked against its source sentence. Each issue has a DOI.

Cover of the ENCLAI Evidence Digest, October 2026
Issue 2026-10 · October 2026

Four developments that shaped October

  • Women's & reproductive health: CCHF in pregnancy linked to 28.8% maternal death and 57.4% fetal loss in meta-analysis
  • Oncology: Felzartamab plus lenalidomide-dexamethasone extends progression-free survival in relapsed or refractory multiple myeloma
  • Neurology: JUVMO approved for Parkinson’s disease in adults
  • Infectious disease: Long-acting HIV injections match oral pills for viral suppression in African adults with adherence challenges
DOI 10.5281/zenodo.23931904 · ENCLAI ID ENCLAI-2026-0000752-8
Cover of the ENCLAI Evidence Digest, September 2026
Issue 2026-09 · September 2026

Four developments that shaped September

  • Oncology: Retlirafusp alfa plus chemotherapy extends survival in HER2-negative gastric cancer
  • Respiratory: Inhaled treprostinil slows lung function loss in IPF
  • Neurology: Isembyld: FDA approval for spinal muscular atrophy in patients on SMN2 therapy
  • Vaccines: Silevimig matches human rabies immunoglobulin in phase III trial
DOI 10.5281/zenodo.23073603 · ENCLAI ID ENCLAI-2026-0000476-5